AbbVie Inc. and Bristol-Myers Squibb Company: A Detailed Gross Profit Analysis

Pharma Giants' Profit Battle: AbbVie vs. Bristol-Myers

__timestamp	AbbVie Inc.	Bristol-Myers Squibb Company
Wednesday, January 1, 2014	15534000000	11947000000
Thursday, January 1, 2015	18359000000	12651000000
Friday, January 1, 2016	19805000000	14481000000
Sunday, January 1, 2017	21176000000	14710000000
Monday, January 1, 2018	25035000000	16014000000
Tuesday, January 1, 2019	25827000000	18067000000
Wednesday, January 1, 2020	30417000000	30745000000
Friday, January 1, 2021	38751000000	36445000000
Saturday, January 1, 2022	40640000000	36022000000
Sunday, January 1, 2023	33903000000	34313000000
Monday, January 1, 2024	0	48300000000

Unveiling the hidden dimensions of data

A Tale of Two Giants: AbbVie Inc. vs. Bristol-Myers Squibb Company

In the ever-evolving pharmaceutical industry, the battle for market dominance is fierce. From 2014 to 2023, AbbVie Inc. and Bristol-Myers Squibb Company have been at the forefront, showcasing impressive growth in gross profit. AbbVie Inc. started with a gross profit of approximately $15.5 billion in 2014, surging to a peak of $40.6 billion in 2022, marking a staggering 162% increase. Meanwhile, Bristol-Myers Squibb Company, with a more modest start of $11.9 billion in 2014, reached $36.4 billion in 2021, a remarkable 206% growth. However, 2023 saw a slight dip for both, with AbbVie at $33.9 billion and Bristol-Myers at $34.3 billion. This analysis highlights the dynamic nature of the pharmaceutical sector, where strategic innovations and market adaptations are key to sustaining growth.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025